{"id":322030,"date":"2020-08-18T10:00:00","date_gmt":"2020-08-18T08:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/sindrome-de-von-willebrand-com-uma-impressionante-historia-de-hemorragia\/"},"modified":"2020-08-18T10:00:00","modified_gmt":"2020-08-18T08:00:00","slug":"sindrome-de-von-willebrand-com-uma-impressionante-historia-de-hemorragia","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/sindrome-de-von-willebrand-com-uma-impressionante-historia-de-hemorragia\/","title":{"rendered":"S\u00edndrome de Von Willebrand com uma impressionante hist\u00f3ria de hemorragia"},"content":{"rendered":"<p><strong>Um paciente que j\u00e1 tinha sofrido quatro abortos relacionados com complica\u00e7\u00f5es hemorr\u00e1gicas apresenta-se para rastreio de trombofilia na 6\u00aa semana de gesta\u00e7\u00e3o. Durante o diagn\u00f3stico, \u00e9 detectada a s\u00edndrome de Von Willebrand, que deve ser tomada em considera\u00e7\u00e3o no decurso da gravidez, durante o parto e no puerp\u00e9rio.<\/strong><\/p>\n<p><!--more--><\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-13894\" style=\"height: 603px; width: 600px;\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0.png\" alt=\"\" width=\"1100\" height=\"1105\" srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0.png 1100w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-800x804.png 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-80x80.png 80w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-120x120.png 120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-90x90.png 90w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-320x320.png 320w, https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/fall3_0-560x563.png 560w\" sizes=\"(max-width: 1100px) 100vw, 1100px\" \/><\/p>\n<table style=\"width: 508px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 161px;\">\n<div><strong>Valores laboratoriais<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>Linha de base<\/strong><\/div>\n<div>(10.12.2018)<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>23. SSW<\/strong><\/div>\n<div>(20.03.2019)<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>29TH SSW<\/strong><\/div>\n<div>(06.05.2019)<\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>aPTT<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>26s<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>25s<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>24s<\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>FVIII:C<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>123%<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>231%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>238%<\/strong><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>VWF:Ag<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>106.0%<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>185.5%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>196.8%<\/strong><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>VWF:RCo<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>49.1%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>52.8%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>60.9%<\/strong><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>VWF:CBA<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>46.0%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>53.2%<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>63.7%<\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>VWF:RCo\/VWF:Ag Ratio<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>0.5<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>0.3<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>0.3<\/strong><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>Actividade Prote\u00edna S<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>45.3%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>Prote\u00edna S livre<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>51.9%<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>D-dimers<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>2,27 mg\/L<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>2,67 mg\/L<\/strong><\/div>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 161px;\">\n<div>PFA-100<\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>231s\/147s<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div><strong>167s\/110s<\/strong><\/div>\n<\/td>\n<td style=\"width: 116px;\">\n<div>N.A.<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div><\/div>\n<div><span style=\"font-size: 11px;\">Uma vis\u00e3o geral com intervalos de refer\u00eancia espec\u00edficos para a idade gestacional pode ser encontrada em<\/span><\/div>\n<div><span style=\"font-size: 11px;\">Szecsi PB et al: Intervalos de refer\u00eancia hemost\u00e1ticos na gravidez.&nbsp;Thromb Haemost. 2010;103(4):718-727.<\/span><\/div>\n<table style=\"width: 588px;\" border=\"1\" cellspacing=\"1\" cellpadding=\"3\">\n<tbody>\n<tr>\n<td style=\"width: 574px;\"><strong>Coment\u00e1rio de Rosa Sonja Alesci, MD<\/strong><\/p>\n<p><img decoding=\"async\" style=\"float: left; height: 150px; width: 156px;\" data-src=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/field\/images\/1drmedrosasonjaalesci.png\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">A s\u00edndrome de Von Willebrand \u00e9 significativamente subdiagnosticada em geral, como este caso de uma paciente do sexo feminino de 33 anos tamb\u00e9m demonstra. Muitos doentes acostumaram-se aos sintomas e n\u00e3o consultam um m\u00e9dico. N\u00e3o \u00e9 raro, por exemplo, que a s\u00edndrome de Von Willebrand seja diagnosticada como um achado incidental durante o rastreio trombofilia no contexto de abortos habituais. No presente caso, especialmente tendo em conta os quatro abortos anteriores com hemorragias e o historial de hemorragias muito impressionante, a substitui\u00e7\u00e3o do factor Von Willebrand durante a gravidez foi indispens\u00e1vel. Al\u00e9m disso, a paciente teve de ser acompanhada de perto, especialmente no in\u00edcio, porque&nbsp;era tamb\u00e9m conhecida por ter trombofilia. Isto tornou poss\u00edvel responder a circunst\u00e2ncias individuais e reagir rapidamente a complica\u00e7\u00f5es consp\u00edcuas. Globalmente, o presente caso mostra que o factor Von Willebrand recombinante (Veyvondi\u00ae) tamb\u00e9m pode ser utilizado com sucesso num tipo raro de s\u00edndrome de Von Willebrand. Ap\u00f3s quatro abortos anteriores, a hemorragia vaginal durante a gravidez p\u00f4de ser tratada de forma \u00f3ptima e o parto foi tamb\u00e9m sem complica\u00e7\u00f5es. N\u00e3o ocorreram efeitos secund\u00e1rios tromb\u00f3ticos e o Veyvondi\u00ae tamb\u00e9m poderia ser administrado no puerp\u00e9rio sem qualquer problema.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><img decoding=\"async\" class=\"image-article-default-image lazyload\" style=\"height: 234px; width: 600px;\" data-src=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/field\/images\/berechnung_1357.png\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\"><\/p>\n<p><span style=\"font-size: 10px;\">Ver tamb\u00e9m informa\u00e7\u00e3o t\u00e9cnica actual VEYVONDI<\/span><sup>\u00ae<\/sup><span style=\"font-size: 10px;\">&nbsp;<\/span><a style=\"font-size: 10px;\" href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a><\/p>\n<p><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Abreviaturas<\/span><\/strong><\/p>\n<p><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">aPTT = tempo de tromboplastina parcial activada; FVIII:C = actividade de factor VIII; GI = gastrointestinal; IU = unidade internacional; PFA-100 = Analisador de fun\u00e7\u00e3o plaquet\u00e1ria 100; VWF:Ag = antig\u00e9nio de factor von Willebrand; VWF:CBA = actividade de liga\u00e7\u00e3o de colag\u00e9nio de factor von Willebrand; VWF:RCo = actividade de co-factor de factor ristocetina de von Willebrand; CNS = sistema nervoso central.<\/span><\/p>\n<p><img decoding=\"async\" class=\"size-full wp-image-13895 lazyload\" style=\"--smush-placeholder-width: 1100px; --smush-placeholder-aspect-ratio: 1100\/368;height: 67px; width: 200px;\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/08\/takeda_logo_rgb.png\" alt=\"\" width=\"1100\" height=\"368\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\"><\/p>\n<p><span style=\"font-size: 11px;\">C-APROM\/CH\/\/0782 &nbsp;07\/2020&nbsp;<\/span><\/p>\n<p><strong><br \/>\n  <span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">VEYVONDI<\/span><br \/>\n<\/strong><strong><br \/>\n  <span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\"><sup>\u00ae<\/sup> <\/span><br \/>\n<\/strong><strong><br \/>\n  <span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Breve informa\u00e7\u00e3o t\u00e9cnica<\/span><br \/>\n<\/strong><\/p>\n<p><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Z:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Subst\u00e2ncia activa: Vonicogum alfa.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">I:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Tratamento da hemorragia ou hemorragia devida a cirurgia no<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Willebrand<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">doen\u00e7a quando a terapia com desmopressina (DDAVP) por si s\u00f3 \u00e9 ineficaz ou contra-indicada.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">D:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">A dosagem e frequ\u00eancia devem ser determinadas individualmente em fun\u00e7\u00e3o da avalia\u00e7\u00e3o cl\u00ednica e com base no peso do paciente, tipo e gravidade dos epis\u00f3dios de hemorragia\/interven\u00e7\u00e3o cir\u00fargica e com base na monitoriza\u00e7\u00e3o de medi\u00e7\u00f5es cl\u00ednicas e laboratoriais adequadas; administra\u00e7\u00e3o intravenosa.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">IA:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Hipersensibilidade \u00e0 subst\u00e2ncia activa ou a um dos excipientes. Reac\u00e7\u00e3o al\u00e9rgica conhecida ao rato<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211; <\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">ou prote\u00ednas de hamster. <\/span><strong><br \/>\n  <span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">VM: <\/span><br \/>\n<\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">H\u00e1 hipersensibilidade<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211; <\/span> <span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">ou reac\u00e7\u00f5es al\u00e9rgicas que podem progredir para anafilaxia grave. Monitorizar de perto os pacientes durante a infus\u00e3o. Os anticorpos neutralizantes podem ser formados contra o Von<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Willebrand<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Factor de desenvolvimento. H\u00e1 um risco de eventos tromb\u00f3ticos.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">SS:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Utilizar apenas com indica\u00e7\u00e3o clara.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">UW:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">A partir de<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Willebrand<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Inibidores de factores, hipersensibilidade<\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">&#8211;  <\/span><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">ou reac\u00e7\u00f5es al\u00e9rgicas, tremores, hipertens\u00e3o, vertigens, trombose venosa profunda, altera\u00e7\u00f5es do ECG.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">AI:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">N\u00e3o h\u00e1 interac\u00e7\u00f5es conhecidas.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">P:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Liofilizado com 650 U.I. ou 1,300 U.I. com 5 ml (resp. 10 ml para 1,300 U.I.) de \u00e1gua para injec\u00e7\u00e3o. Levy categoria B.  <\/span><strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Z:  <\/span><\/strong><span style=\"font-family: ubuntu,sans-serif; font-size: 8pt;\">Takeda Pharma AG, 8152 Opfikon. Pode encontrar informa\u00e7\u00e3o detalhada em  <\/span><span style=\"color: #954f72; font-family: ubuntu,sans-serif; font-size: 8pt;\"><a style=\"color: #954f72;\" href=\"http:\/\/www.swissmedicinfo.ch\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Um paciente que j\u00e1 tinha sofrido quatro abortos relacionados com complica\u00e7\u00f5es hemorr\u00e1gicas apresenta-se para rastreio de trombofilia na 6\u00aa semana de gesta\u00e7\u00e3o. Durante o diagn\u00f3stico, \u00e9 detectada a s\u00edndrome de&hellip;<\/p>\n","protected":false},"author":7,"featured_media":96999,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Relato de caso: Gravidez e nascimento","footnotes":""},"category":[11536,11524,11419,11365,11551],"tags":[11739,11740],"powerkit_post_featured":[],"class_list":["post-322030","post","type-post","status-publish","format-standard","has-post-thumbnail","category-casos-pt-pt","category-formacao-continua","category-ginecologia-pt-pt","category-hematologia-pt-pt","category-rx-pt","tag-sindrome-de-willebrand-pt-pt","tag-veyvondi-pt-pt","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-03 07:32:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":322028,"slug":"sindrome-de-von-willebrand-con-antecedentes-hemorragicos-impresionantes","post_title":"S\u00edndrome de von Willebrand con antecedentes hemorr\u00e1gicos impresionantes","href":"https:\/\/medizinonline.com\/es\/sindrome-de-von-willebrand-con-antecedentes-hemorragicos-impresionantes\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/322030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=322030"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/322030\/revisions"}],"predecessor-version":[{"id":323259,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/322030\/revisions\/323259"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/96999"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=322030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=322030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=322030"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=322030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}